Concerto HealthAI has inked its second real-world data collaboration with a Big Pharma company in as many weeks, this time to help Pfizer select patients for its precision oncology development work.
Concerto, a SymphonyAI company, aims to design more efficient clinical trials using prefabricated control arms and data from electronic medical records and insurance claims, as well as economic outcome measures, all through the use of artificial intelligence and machine learning.
In late March, the company signed on to a multi-year project with Bristol-Myers Squibb focusing on a range of different cancers. At Pfizer, Concerto’s work will cover investigational and approved treatments, across both solid and blood tumors.
The project will also look to identify new patient subpopulations for combination cancer therapy trials, according to a statement from Concerto CEO Jeff Elton, and includes plans to design and conduct real-world outcomes studies using synthetic control arms, with the first results expected early next year.
In addition to other sources, Concerto’s eurekaHealth platform incorporates data under license from the American Society of Clinical Oncology’s CancerLinQ program, a quality monitoring system that collects patient encounter data. Through a separate collaboration with ASCO, the FDA and the tech firm Tempus, Concerto is also working to broaden the use of real-world evidence in pre- and post-approval studies.
Concerto and Tempus, a molecular data repository builder, are currently working with the FDA analyze de-identified CancerLinQ data covering more than 10,000 patients treated with immune system checkpoint inhibitors.
Pfizer, meanwhile, has been exploring the use of real-world data through a number of partnerships, including with BC Platforms in cardiovascular disease, the cloud-based TriNetX global clinical research network, and IBM for the development of remote patient monitoring sensors.